Exicure Files Form 12b-25
November 15 2021 - 5:48PM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR) today announced that it has filed
a Form 12b-25 with the U.S. Securities and Exchange Commission (the
“SEC”) in connection with its Quarterly Report on Form 10-Q for the
period ended September 30, 2021 (the “Form 10-Q”).
Exicure, Inc. (the “Company”) is unable to file its Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021 (the
“Q3 2021 10-Q”) with the SEC within the prescribed time period
without unreasonable effort or expense. On November 9, 2021, the
Audit Committee of the Board of Directors of the Company was
notified of a claim made by a former Company senior researcher
regarding alleged improprieties that researcher claims to have
committed with respect to the Company’s XCUR-FXN preclinical
program for the treatment of Friedreich’s ataxia. The Audit
Committee has retained external counsel to conduct an internal
investigation of the claim. The Company is currently unable to
predict the timing or outcome of the investigation. Despite working
diligently in an effort to timely file its Q3 2021 10-Q, the
Company requires additional time to complete certain disclosures
and procedures, including disclosures relating to the internal
investigation.
The Company expects to file its Q3 2021 10-Q with the SEC as
soon as practicable, and no later than the fifth calendar day
following the prescribed due date, in accordance with Rule
12b-25.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA. For more information,
visit Exicure’s website at www.exicuretx.com.
Exicure Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release other than statements of
historical fact could be deemed forward looking including, but not
limited to, statements regarding the Company’s preliminary results
for the third quarter of 2021 and the Company’s anticipated timing
for filing its Q3 2021 10-Q, statements regarding the internal
investigation being conducted by the Audit Committee including, but
not limited to, the timing and scope of the investigation; and the
Company’s business plans and objectives. Words such as “plans,”
“expects,” “will,” “anticipates,” “continue,” “expand,” “advance,”
“believes,” “guidance,” “target,” “may,” “remain,” “project,”
“outlook,” “intend,” “project,” “estimate,” “could,” “should,” and
other words and terms of similar meaning and expression are
intended to identify forward-looking statements, although not all
forward-looking statements contain such terms. The forward-looking
statements in this press release speak only as of the date of this
press release, and the Company undertakes no obligation to update
these forward-looking statements. Forward-looking statements are
based on management’s current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the time necessary for the
Audit Committee to complete its investigation and review; the
diversion of management attention to the internal investigation;
the final conclusions and outcome of the Audit Committee and board
of directors following the completion of its investigation and
review, including any related investigations or proceedings. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause the Company’s actual results to differ from those
contained in the forward-looking statements, see the section titled
“Risk Factors” in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2020, as updated by the Company’s
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and the Company undertakes no duty to update this information or to
publicly announce the results of any revisions to any of such
statements to reflect future events or developments, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211115006324/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024